men and women respectively were -2.84 +/- 0.10 mg/dL and -3.03 +/- 0.10 mg/dL for total cholesterol, - 3.78 +/- 0.30 mg/dL and - 2.26 +/- 0.19 mg/dL for triglycerides, and - 2.54 +/- 0.09 mg/dL and - 3.06 +/- 0.09 mg/dL for LDL-cholesterol (all P < 10(-1)6 ). ...
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010). Google Scholar Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. ...
After adjusting for age, sex and treatment arm, plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), insulin, neopterin, N-terminal pro-brain natriuretic peptide (BNP), lipoprotein(a) [Lp(a)], and the soluble receptor for ...
Aim: This report investigated the relationship between anthropometric measurements of body fat distribution and lipid response to statins in hypercholesterolemic hypertensive patients. Methods: We prospectively examined 129 subjects who used either simvastatin 20 mg/day (no.=83) or atorvastatin 10 mg/day...
For a target LDL-C reduction of < 30%: Low-intensity statin therapy, including any of the following: Simvastatin 10 mg Pravastatin 10 to 20 mg Lovastatin 20 mg Fluvastatin 20-40 mg Indications The 2018 ACC/AHA/Multisociety cholesterol guideline provides the following recommendations for the use...
Statin therapy improves cholesterol efflux from macrophages and ameliorates PAP inCsf2rb−/− mice.a–gMice received oral statin therapy for 6 weeks or untreated age-matchedCsf2rb−/− or wild type (WT) mice. Disease severity evaluated by bronchoalveolar lavageaturbidity andbtotal cholesterol...
These recommendations do not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (4.92 mmol/L) or known familial hypercholesterolemia. These populations are at very high risk for CVD, and considerations on the use of statins in these populations can...
The first issue to address is the mechanism by which statins reduce venous (VTE) whether by lowering LDL cholesterol or by another mechanism. Meta-analyses of RCTs (Kunutsor 2017) show significant risk reductions for VTE with statins in adult populations. However, the mechanism is still not ...
analysis of data from a randomized, double-blind, placebo-controlled trial designed to evaluate the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of adding ezetimibe 10 mg/day versus placebo to ongoing, open-label statin treatment for 8 weeks in hypercholesterolemic ...
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622. doi:10.1001/jama.279.20.1615ArticlePubMedGoogle ScholarCrossref 18. Furberg C; ALLHAT Officers and Coordinators for the...